Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 1:50 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1921–1944 of 79,351 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: 2 Clear all

Conditions: Malignant Neoplasm
Interventions: Opevesostat, Fludrocortisone/ Fludrocortisone acetate, Dexamethasone/Dexamethasone acetate, Rescue Medications, Fulvestrant, Exemestane, Megestrol acetate/Medroxyprogesterone acetate, Tamoxifen, Letrozole; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 10
States / cities: Anchorage, Alaska • Miami Beach, Florida • Shreveport, Louisiana + 6 more

Conditions: Melanoma, Malignant Metastatic Melanoma
Interventions: MEDI--522, Integrin + Dacarbazine; Biological
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 25
States / cities: Scottsdale, Arizona • Long Beach, California • San Francisco, California + 20 more

Conditions: Sphincter of Oddi Dysfunction
Interventions: ERCP with sphincterotomy, ERCP without sphincterotomy; Procedure
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years to 65 Years
Enrollment: 214 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2016
U.S. locations: 7
States / cities: New Haven, Connecticut • Indianapolis, Indiana • Minneapolis, Minnesota + 4 more

Conditions: Bacterial Vaginosis
Interventions: Vitamin D3 (cholecalciferol), Placebo; Dietary Supplement
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 118 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Tobacco Smoking
Interventions: Financial incentives, Varenicline, Tobacco coaching; Behavioral · Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 184 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Stage III Chronic Lymphocytic Leukemia, Stage III Small Lymphocytic Lymphoma, Stage IV Chronic Lymphocytic Leukemia, Stage IV Small Lymphocytic Lymphoma
Interventions: Bendamustine Hydrochloride, Alemtuzumab; Drug · Biological
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2013
U.S. locations: 2
States / cities: Cleveland, Ohio

Conditions: Chronic Headaches
Interventions: Behavioral Treatment for Chronic Headache- Exercise Version; Behavioral
Lead sponsor: University of Mississippi Medical Center; Other
Eligibility: 18 Years to 64 Years · Female only
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Jackson, Mississippi

Conditions: Obesity
Interventions: Cetrorelix, Gonadorelin-GnRH, Recombinant LH, Letrozole; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 62 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Sepsis
Interventions: piperacillin-tazobactam; Drug
Lead sponsor: Phillip Brian Smith; Other
Eligibility: Up to 60 Days
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 4
States / cities: Indianapolis, Indiana • Wichita, Kansas • Kansas City, Missouri + 1 more

Conditions: Warm Antibody Autoimmune Hemolytic Anemia
Interventions: Fostamatinib disodium; Drug
Lead sponsor: Rigel Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 8
States / cities: Los Angeles, California • Torrance, California • Washington D.C., District of Columbia + 5 more

Conditions: COVID-19
Interventions: NVX-CoV2373 (5μg), NVX-CoV2601(5μg), NVX-CoV2601(35μg), NVX-CoV2601(50μg), Bivalent BA.4/5; Biological
Lead sponsor: Novavax; Industry
Eligibility: 50 Years to 99 Years
Enrollment: 994 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 50
States / cities: Birmingham, Alabama • Tucson, Arizona • Banning, California + 44 more

Conditions: Suicide Prevention
Interventions: Cognitive Reappraisal Intervention for Suicide Prevention, Supportive Therapy; Behavioral
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 50 Years to 90 Years
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 1
States / cities: White Plains, New York

Conditions: Cataract Surgery Anesthesia
Interventions: Arm 1 Cataract Surgery performed with remimazolam as sedative, Arm 2 Cataract Surgery performed with standard of care sedative; Drug
Lead sponsor: Fred E, Shapiro; Other
Eligibility: 55 Years to 90 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Multiple Sclerosis
Interventions: Telephone-based Cognitive Behavioral Therapy, Modafinil; Behavioral · Drug
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 343 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 2
States / cities: Ann Arbor, Michigan • Seattle, Washington

Conditions: Peanut Allergy
Interventions: Whole peanut extract, Placebo formulation; Biological
Lead sponsor: DBV Technologies; Industry
Eligibility: 6 Years to 50 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 5
States / cities: Little Rock, Arkansas • Denver, Colorado • Willingboro, New Jersey + 2 more

Conditions: Hepatitis B, Chronic
Interventions: JNJ-73763989, Placebo for JNJ-73763989, JNJ-56136379, Placebo for JNJ-56136379, Nucleos(t)ide Analog (NA); Drug
Lead sponsor: Janssen Sciences Ireland UC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 471 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 8
States / cities: Bakersfield, California • Los Angeles, California • San Clemente, California + 5 more

Conditions: Multiple Sclerosis
Interventions: Placebo, 10 milligram (mg) fampridine-SR (4-aminopyridine, 4-AP), 15 mg fampridine-SR (4-aminopyridine, 4-AP), 20 mg fampridine-SR (4-aminopyridine, 4-AP); Drug
Lead sponsor: Acorda Therapeutics; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 206 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003
U.S. locations: 23
States / cities: Phoenix, Arizona • Los Angeles, California • New Haven, Connecticut + 19 more

Conditions: Blood Stem Cell Transplant Failure, Leukemia, Hematologic Malignancies
Interventions: Cyclophosphamide, Fludarabine, Melphalan, Mesna, Rituximab, Stem Cell Transplantation, Thiotepa, Tacrolimus, Mycofenolate mofetil, G-CSF; Drug · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Up to 75 Years
Enrollment: 176 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2017
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Non Small Cell Lung Carcinoma
Interventions: TLK286 (Telcyta) HCl for Injection, gefitinib (Iressa); Drug
Lead sponsor: Telik; Industry
Eligibility: 18 Years and older
Enrollment: 520 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2005
U.S. locations: 270
States / cities: Birmingham, Alabama • Glendale, Arizona • Benton, Arkansas + 174 more

Conditions: Substance Use Disorders, Overdose
Interventions: POINT; Behavioral
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 249 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 2
States / cities: Indianapolis, Indiana • Muncie, Indiana

Conditions: Cytomegalovirus Retinitis, HIV Infections
Interventions: Ganciclovir; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years to 60 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1995
U.S. locations: 5
States / cities: San Diego, California • San Francisco, California • New York, New York

Conditions: Melanoma (Skin)
Interventions: therapeutic autologous lymphocytes, Use of an artificial antigen presenting cell (aAPC) to generate CTL, GM-CSF, Irradiation of cutaneous tumor lesion; Biological · Genetic · Drug + 1 more
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Healthy
Interventions: LY2541546 - SC, LY2541546 - IV, Placebo - SC, Placebo - IV; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 45 Years to 80 Years · Female only
Enrollment: 59 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 5
States / cities: Daytona Beach, Florida • Honolulu, Hawaii • Evansville, Indiana + 2 more

Conditions: Respiratory Syncytial Virus Infections
Interventions: MVA BN RSV, Placebo; Biological · Other
Lead sponsor: Bavarian Nordic; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 63 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Lenexa, Kansas

Search by objective public record fields.

A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)

Evaluating The Antitumor Activity Of MEDI-522 With Or Without Dacarbazine In Patients With Metastatic Melanoma

Evaluating Predictors & Interventions in Sphincter of Oddi Dysfunction

Vitamin D and Sexual Health

Financial Incentives for Homeless Smokers: A Community-based RCT

Bendamustine Plus Alemtuzumab for Refractory Chronic Lymphocytic Leukemia (CLL)

Effects of Aerobic Exercise Within a Behavioral Treatment Program for Chronic Headaches

Reproductive Hormonal Alterations in Obesity

Pharmacokinetics and Safety of Piperacillin-tazobactam in Neonates

A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia

Phase 2/3 Heterologous Boosting Study With Different Dose Levels of Monovalent SARS-CoV-2 rS Vaccines

A Novel Cognitive Reappraisal Intervention for Suicide Prevention

Study of Remimazolam for Cataract Surgery

Cognitive Behavioral Therapy, Modafinil, or Both for Multiple Sclerosis Fatigue

Safety of Epicutaneous Immunotherapy for the Treatment of Peanut Allergy

A Study of Different Combination Regimens Including JNJ-73763989 and/or JNJ-56136379 for the Treatment of Chronic Hepatitis B Virus Infection

Safety and Efficacy Study of Oral Fampridine-SR in Patients With Multiple Sclerosis

Mismatched Transplantation Using High-dose Post-transplant Cyclophosphamide

Study of TLK286 (Telcyta) vs. Gefitinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Project POINT: Effectiveness and Scalability of an Overdose Survivor Intervention

A Phase I Pharmacokinetic and Tolerance Study of 28-Day Regimens of Oral Ganciclovir

Adoptive Transfer of MART1/Melan-A CTL for Malignant Melanoma

A Multiple Dose Study of LY2541546 in Healthy Postmenopausal Women

Trial to Evaluate the Safety, Tolerability and Immunogenicity of the Recombinant MVA BN® RSV Vaccine